Publikationer Jan-Håkan Jansson


Wennberg P, Wensley F, Johansson L, Boman K, Angelantonio ED, Rumley A, Lowe G, Hallmans G, Jansson JH. Reduced risk of myocardial infarction related to active commuting: inflammatory and haemostatic effects are potential major mediating mechanisms. Eur J Cardiovasc Prev Rehabil. 2009 Oct 8.

Lind M, Boman K, Johansson L, Nilsson TK, Ohlin AK, Birgander LS, Jansson JH. Thrombomodulin as a marker for bleeding complications during warfarin treatment. Arch Intern Med. 2009 Jul 13;169(13):1210-5.
Lindahl B, Nilsson T, Borch-Johnsen K, Roder ME, Soderberg S, Widman L, Johnson O, Hallmans G, Jansson JH. A randomized lifestyle intervention with 5-year follow-up in subjects with impaired glucose tolerance: Pronounced short-term impact but long-term adherence problems. Scand J Public Health. 2009 Jan 30.

Van Guelpen B, Hultdin J, Johansson I, Witthoft C, Weinehall L, Eliasson M, Hallmans G, Palmqvist R, Jansson JH, Winkvist A. Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function. J Intern Med. 2009 Aug;266(2):182-95.

Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. Jama. 2009 Nov 11;302(18):1993-2000.
Gronlund H, Hallmans G, Jansson JH, Boman K, Wikstrom M, de Faire U, et al. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):382-6.

Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Jama. 2009 Jul 22;302(4):412-23.
Andersson J, Jansson JH, Hellsten G, Nilsson TK, Hallmans G, Boman K. Effects of heavy endurance physical exercise on inflammatory markers in non-athletes. Atherosclerosis. 2009 Oct 29.

Hernestal Boman J, Jansson JH, Nilsson TK, Eliasson M, Johansson L. Long-term stability of fibrinolytic factors stored at -80°C. Thrombosis Research. 2009.

Boman K, Jansson JH, Nilsson T, Swedberg K, Cleland JG, Poole-Wilson P. Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure - a COMET substudy. Thromb Res. 2009 Sep 15.
Nilsson LM, Wennberg M, Lindahl B, Eliasson M, Jansson JH, Van Guelpen B. Consumption of filtered and boiled coffee and the risk of first acute myocardial infarction; a nested case/referent study. Nutr Metab Cardiovasc Dis. 2009 Aug 18.
Thogersen AM, Nilsson TK, Weinehall L, Boman K, Eliasson M, Hallmans G, Jansson JH. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years. Blood Coagul Fibrinolysis. 2009 Jul;20(5):340-6.
Lundblad D, Holmgren L, Jansson JH, Naslund U, Eliasson M. Gender differences in trends of acute myocardial infarction events: The Northern Sweden MONICA study 1985 - 2004. BMC Cardiovasc Disord. 2008 Jul 25;8(1):17.
Sjalander A, Jansson JH, Bergqvist D, Eriksson H, Carlberg B, Svensson P. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis. J Intern Med. 2008 Jan;263(1):52-60.
Andersson J, Boman K, Jansson JH, Nilsson TK, Lindahl B. Effect of intensive lifestyle intervention on C-reactive protein in subjects with impaired glucose tolerance and obesity. Results from a randomized controlled trial with 5-year follow-up. Biomarkers. 2008 Nov;13(7):671-9.
Wennberg P, Eliasson M, Hallmans G, Johansson L, Boman K, Jansson JH. The risk of myocardial infarction and sudden cardiac death amongst snuff users with or without a previous history of smoking. J Intern Med. 2007 Sep;262(3):360-7.
Trichopoulou A, Bamia C, Norat T, Overvad K, Schmidt EB, Tjonneland A, Halkjaer J, Clavel-Chapelon F, Vercambre MN, Boutron-Ruault MC, Linseisen J, Rohrmann S, Boeing H, Weikert C, Benetou V, Psaltopoulou T, Orfanos P, Boffetta P, Masala G, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Ocke MC, Peeters PH, Van der Schouw YT, Gonzalez C, Sanchez MJ, Chirlaque MD, Moreno C, Larranaga N, Van Guelpen B, Jansson JH, Bingham S, Khaw KT, Spencer EA, Key T, Riboli E, Trichopoulos D. Modified Mediterranean diet and survival after myocardial infarction: the EPIC-Elderly study. Eur J Epidemiol. 2007 Oct 10.

Nilsson JB, Boman K, Jansson JH, Nilsson T, Naslund U. The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase. J Thromb Thrombolysis. 2007 Aug 25.
Wennberg M, Bergdahl IA, Stegmayr B, Hallmans G, Lundh T, Skerfving S, Stromberg U, Vessby B, Jansson JH. Fish intake, mercury, long-chain n-3 polyunsaturated fatty acids and risk of stroke in northern Sweden. Br J Nutr. 2007 May 31:1-8.
Sjalander A, Jansson JH, Bergqvist D, Eriksson H, Svensson P. [Evidence for thrombosis prophylaxis to high-risk patients]. Lakartidningen. 2007 May 14-29;104(20-21):1585-7.

Själander A, Jansson J, Bergqvist D, Eriksson H, Carlberg B, Svensson P. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolim in acutely ill medical in-patients - a meta-analysis. JIM accepterad. 2007;0338.R2.
Wallvik J, Sjalander A, Johansson L, Bjuhr O, Jansson JH. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care. 2007 Jun;25(2):123-8.
Eliasson M, Janlert U, Jansson JH, Stegmayr B. Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. J Intern Med. 2006;260:551-9.
Wennberg M, Lundh T, Bergdahl IA, Hallmans G, Jansson JH, Stegmayr B, et al. Time trends in burdens of cadmium, lead, and mercury in the population of northern Sweden. Environ Res. 2006 Mar;100(3):330-8.
Ekstedt B, Jansson JH, Boman K. [No scientific evidence supports vitamin B treatment of patients with cardiovascular diseases]. Lakartidningen. 2006 Nov 8-14;103(45):3464-6.
Wennberg P, Lindahl B, Hallmans G, Messner T, Weinehall L, Johansson L, Boman K, Jansson JH. The effects of commuting activity and occupational and leisure time physical activity on risk of myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2006 Dec;13(6):924-30.
Lind M, Jansson JH. [Deep venous thrombosis]. Läkartidningen. 2006;Mar 29-Apr 4;103(13):1031-4.
Claesson M, Birgander LS, Jansson JH, Lindahl B, Burell G, Asplund K, et al. Cognitive-behavioural stress management does not improve biological cardiovascular risk indicators in women with ischaemic heart disease: a randomized-controlled trial. J Intern Med. 2006 Oct;260(4):320-31.
Oldgren J, Fellenius C, Boman K, Jansson JH, Nilsson TK, Wallentin L, et al. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease. J Intern Med. 2005 Nov;258(5):420-7.
Nilsson TK, Boman K, Jansson JH, Thogersen AM, Berggren M, Broberg A, et al. Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte) stored at -70 degrees C for 8-11 years. Thromb Res. 2005;116(3):249-54.
Jansson JH. [Central venous catheter and malignant disease. The value of thrombosis prophylaxis is questioned now]. Lakartidningen. 2005 Jun 27-Jul 10;102(26-27):1984-5.
Custodio HM, Broberg K, Wennberg M, Jansson JH, Vessby B, Hallmans G, et al. Polymorphisms in glutathione-related genes affect methylmercury retention. Arch Environ Health. 2004 Nov;59(11):588-95.
Thogersen AM, Soderberg S, Jansson JH, Dahlen G, Boman K, Nilsson TK, et al. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2004 Feb;11(1):33-40.
Johansson L, Jansson JH, Stegmayr B, Nilsson TK, Hallmans G, Boman K. Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study. Stroke. 2004 Apr;35(4):826-30.
Warensjo E, Jansson JH, Berglund L, Boman K, Ahren B, Weinehall L, et al. Estimated intake of milk fat is negatively associated with cardiovascular risk factors and does not increase the risk of a first acute myocardial infarction. A prospective case-control study. Br J Nutr. 2004 Apr;91(4):635-42.
Hultdin J, Thogersen AM, Jansson JH, Nilsson TK, Weinehall L, Hallmans G. Elevated plasma homocysteine: cause or consequence of myocardial infarction? J Intern Med. 2004 Dec;256(6):491-8.
Jansson JH, Boman K, Messner T. Trends in blood pressure, lipids, lipoproteins and glucose metabolism in the Northern Sweden MONICA project 1986-99. Scand J Public Health. 2003;Suppl 61:43-50.
Jansson JH. [Homocysteine and cardiovascular disease--still no evidence for a connection. An unknown risk factor can be involved according to a systemic review]. Lakartidningen. 2003 May 8;100(19):1721-2.
Eliasson MC, Jansson JH, Lindahl B, Stegmayr B. High levels of tPA antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA Study. Cardiovasc Diabetol. 2003 Dec 22;2(1):19.
Jansson JH. Editorial to the study by Panju A. et al. "Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review". Thromb Res. 2003;111(4-5):213-4.
Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, Jansson JH, et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort - evaluation of risk factors and their interactions. Scand J Public Health. 2003;Suppl 61:18-24.
Ladenvall P, Johansson L, Jansson JH, Jern S, Nilsson TK, Tjarnlund A, et al. Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost. 2002;87(1):105-9.
Nilsson TK, Spence JD, Nilsson PM, Eliasson M, Jansson JH, Boman K. Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma--a 2-year follow-up study. J Cardiovasc Risk. 2002 Aug;9(4):215-21.
Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Prospective study on soluble thrombomodulin and von Willebrand factor and the risk of ischemic and hemorrhagic stroke. Thromb Haemost. 2002 Feb;87(2):211-7.
Boman K, Jansson JH, Nyhlén K, Nilsson TK. Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction. Thromb Haemost. 2002;87:311-6.
Nilsson JB, Nilsson TK, Jansson JH, Boman K, Soderberg S, Naslund U. The effect of streptokinase neutralizing antibodies on fibrinolytic activity and reperfusion following streptokinase treatment in acute myocardial infarction. J Intern Med. 2002 Nov;252(5):405-11.
Soderberg S, Nilsson TK, Nilsson M, Olsson T, Boman K, Jansson JH. The effect of enalapril treatment of fibrinolytic and leptin levels and the impact of gender on the relative changes of these variables. World Congress in Cardiology, Sydney, Austalia. 2002.
SBU-rapport., Jansson JH, medförfattare. Blodpropp - förebyggande, diagnostik och behandling av venös tromboembolism. En systematisk kunskapssammanställning. 2002.
Hallgren CG, Hallmans G, Jansson JH, Marklund SL, Huhtasaari F, Schutz A, et al. Markers of high fish intake are associated with decreased risk of a first myocardial infarction. Br J Nutr. 2001;86(3):397-404.
Thogersen AM, Nilsson TK, Dahlen G, Jansson JH, Boman K, Huhtasaari F, et al. Homozygosity for the C677-->T mutation of 5,10- methylenetetrahydrofolate reductase and total plasma homocyst(e) ine are not associated with greater than normal risk of a first myocardial infarction in northern Sweden. Coron Artery Dis. 2001;12(2):85-90.
Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke. 2000;31(1):26-32.
Jansson JH. [High homocysteine level is not a risk factor of cardiovascular disease]. Lakartidningen. 2000 May 17;97(20):2522.
Jansson JH. [Correct information on vitamin B12?]. Lakartidningen. 2000 Apr 5;97(14):1732.
Soderberg S, Ahren B, Jansson JH, Johnson O, Hallmans G, Asplund K, et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999 Oct;246(4):409-18.
Lindahl B, Nilsson TK, Jansson JH, Asplund K, Hallmans G. Improved fibrinolysis by intensive lifestyle intervension. A randomized trial in subjects with impaired glucose tolerance. JIM. 1999;246:105-12.
Lindahl B, Dinesen B, Eliasson M, Roder M, Jansson JH, Huhtasaari F, et al. High proinsulin concentration preceeds acute myocardial infarction in a non-diabetic population. Metabolism. 1999;48:1197-202.
Jansson JH, Nilsson TK, Johnson O. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart. 1998 Oct;80(4):334-7.
Weinehall L, Johnson O, Jansson JH, Boman K, Huhtasaari F, Hallmans G, et al. Perceived health modifies the effect of biomedical risk factors in the prediction of acute myocardial infarction. An incident case-control study from northern Sweden. J Intern Med. 1998 Feb;243(2):99-107.
Dahlen GH, Weinehall L, Stenlund H, Jansson JH, Hallmans G, Huhtasaari F, et al. Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males. An incident case-control study from Sweden. J Intern Med. 1998 Nov;244(5):425-30.
Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998 Nov 24;98(21):2241-7.
Nilsson JB, Nilsson TK, Naslund U, Jansson JH, Boman K. Relationship between fibrinolytic activity following streptokinase treatment in acute myocardial infarction and vectorcardiographic signs of reperfusion. Fibrinol and proteol. 1997;11(4):193-99.
Eliasson M, Jansson JH, Nilsson P, Asplund K. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden. J Hypertens. 1997;15(4):349-56.
Jansson JH, Boman K, Brannstrom M, Nilsson TK. High concentration of thrombomodulin in plasma is associated with hemorrhage: a prospective study in patients receiving long-term anticoagulant treatment. Circulation. 1997;96(9):2938-43.
Thogersen AM, Jansson JH, Wester PO. Magnesium therapy, fibrinolytic parameters and von Willebrand factor in acute myocardial infarction. Int J Cardiol. 1996 Sep;56(1):53-9.
Jansson JH, Boman K, Brannstrom M, Nilsson TK. Increased levels of plasma thrombomodulin are associated with vascular and all-cause mortality in patients on long-term anticoagulant treatment. Eur Heart J. 1996;17(10):1503-5.
Nilsson TK, Thogersen AM, Jansson JH, Boman K. Comparison of von Willebrand factor and tissue plasminogen activator concentrations in plasma and serum. Clin Chem. 1996 Jun;42(6 Pt 1):976-7.
Bylesjo I, Jansson JH, Schulman S. Trombosrisken ökad vid FXII-brist? Läkartidningen. 1995;92:425.
Jansson JH, Westman G, Boman K, Nilsson T, Norberg B. Oral anticoagulant treatment in a medical care district - a descriptive study. Scand J Prim Health Care. 1995;13(4):268-74.
Brannstrom M, Jansson JH, Boman K, Nilsson TK. Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment. Thromb Haemost. 1995;74(2):612-5.
Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation. 1993 Nov;88(5 Pt 1):2030-4.
Jansson JH, Boman K, Nilsson TK. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol. 1993;44(5):485-8.
Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Brit Heart J. 1991;66:351-55.
Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J. 1991;12(2):157-61.
Jansson JH, Johansson B, Boman K, Nilsson TK. Hypo-fibrinolysis in patients with hypertension and elevated serum cholesterol. J Intern Med. 1991;229(4):309-16.
Jansson JH, Johansson B, Boman K, Nilsson TK. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J of Clin Pharm. 1991;40:321-6.
Jansson JH, Norberg B, Nilsson TK. Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery. Clin Chem. 1989 Jul;35(7):1544-5.
Schulman S, Stigendal L, Jansson JH, Brohult J. Haemorrhagic and thromboembolic complications versus intensity of treatment of venous thromboembolism with oral anticoagulants. Acta Med Scand. 1988;224(5):425-30.
Jansson JH, Eriksson P, Boman K, Eriksson S, Olofsson BO, Sjogren B. Cardiac stimulation threshold in familial amyloidosis with polyneuropathy. Pacing Clin Electrophysiol. 1987;10(4 Pt 1):817-21.

Stöd vår forskning redan idag

Så hjälper du till

Stiftelsen vill inspirera och stödja yngre men även äldre läkare, sjuksköterskor, apotekare med flera till att forska inom områdena medicin och omvårdnad inom Skellefteå sjukvård (kommunerna Skellefteå och Norsjö).

Postgiro & Bankgiro

Stöd vår verksamhet genom att sätta in pengar på följande Post- och Bankgiro:

Stiftelsens postgiro 444 81 29-9
Stiftelsens bankgiro 710-9721
Stiftelsens swish 1233351574
Org nr 89 47 01-2384

Dela vår hemsida

Hjälp vår stiftelse och våra forskare genom att sprida vår sida vidare via sociala medier.
Information om cookies